## STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		Abstract identifies the study as a cross-sectional study
		(b) Provide in the abstract an informative and balanced summary of what was done
		and what was found
		Abstract characterizes the cross-sectional study, provides information on antibody
		bioassays used to determine seroprevalence, and discusses statistical methodology and
		findings.
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
6		SARS-CoV-2 seroprevalence study in a geographically restricted region with high
		infection incidence.
Objectives	3	State specific objectives, including any prespecified hypotheses
5		<i>Characterization of SARS-CoV-2 seroprevalence in the valley population.</i>
		Observational study without construction of prior hypotheses.
Methods		
Study design	4	Present key elements of study design early in the paper
Study design	I	Riology-related methods are addressed first followed by computational methods
		Items 4 5 and 6 are addressed in the first paragraph of the Methods section
Setting	5	X Describe the setting locations and relevant dates including periods of recruitment
Setting	5	exposure follow-up and data collection
		Population size and number of invited participants given immediately
Participants	6	X(a) Give the eligibility criteria, and the sources and methods of selection of
1 articipants	0	participants
		Sample selection is described: eligibility criteria: place of residence: age > 6: non-
		pregnant women
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
		modifiers. Give diagnostic criteria, if applicable
		Derivation of descriptive variables, definition of strata and use of regression tests are
		addressed in a section on statistical analyses. Measurement of SARS-CoV-2 exposure
		is detailed in the biology section.
Data sources/	8*	For each variable of interest, give sources of data and details of methods of
measurement		assessment (measurement). Describe comparability of assessment methods if there is
		more than one group
		Variables are obtained from a questionnaire, which is available as a supplement.
		SARS-CoV-2 exposure is measured by using nasopharyngeal swab and serum antibody
		tests.
Bias	9	Describe any efforts to address potential sources of bias
		Various types of possible bias were accounted for in the Methods, both at the study
		design phase and in the post collection data analyses (see Statistical analyses section).
		The Discussion section discusses additional potential sources of bias that could not be
		accounted for.
Study size	10	Explain how the study size was arrived at
		Sample size determination is described in the first paragraph of the Methods section.
Quantitative	11	Explain how quantitative variables were handled in the analyses. If applicable,

variables		describe which groupings were chosen and why
		When applicable, manufacturers thresholds were chosen for deriving groupings and
		any deviations are clearly marked and discussed. Age groups include non-adults and
		elderly as separate strata.
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
		Descriptive statistics, derivation of confidence intervals and regression tests are
		detailed in the Methods (Statistical analyses section) and table footers.
		(b) Describe any methods used to examine subgroups and interactions
		$\sum_{i=1}^{n} (i)^{i}$ Describe any methods used to examine subgroups and interactions and a separate
		araph is dedicated to their interpretation ROC analyses on serum antibodies split
		subrouns by age and sex in separate graphs
		$\overline{X(c)}$ Explain how missing data were addressed
		Missing data were addressed by using non-response corrected sampling weights in all
		analyses
		$\Sigma(d)$ If applicable, describe analytical methods taking account of sampling strategy
		$\Delta(a)$ in applicable, describe analytical methods taking account of sampling strategy
		Logistic regression models were survey set based on sample stratification and weight
		aujustea accounting also for post-strainfication variables.
		$\underline{\mathbb{N}}(\underline{e})$ Describe any sensitivity analyses
		we controlled if there was any evidence of a different estimated seroprevalence
		between completers and non-completers of the questionnaire interview.
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially
		eligible, examined for eligibility, confirmed eligible, included in the study, completing
		follow-up, and analysed
		Numbers are clearly stated.
		$\boxtimes$ (b) Give reasons for non-participation at each stage
		Reasons for non-participation are listed.
		$\square$ (c) Consider use of a flow diagram
		Given the workflow is straightforward, we explained it in the text.
Descriptive data	14*	$\bigotimes$ (a) Give characteristics of study participants (eg demographic, clinical, social) and
		information on exposures and potential confounders
		The first part of the Results section and Table 1 provide all descriptive data.
		$\bigotimes$ (b) Indicate number of participants with missing data for each variable of interest
		Missingness for the main outcomes is reported at the beginning of the results.
		Missingness for any variable of interest is indicated in the results tables or was
		accounted for in the statistical models
Outcome data	15*	Report numbers of outcome events or summary measures
		Table 2 provides these data.
Main results	16	$\square(a)$ Give unadjusted estimates and, if applicable, confounder-adjusted estimates and
		their precision (eg, 95% confidence interval). Make clear which confounders were
		adjusted for and why they were included
		To be found in Tables 3 and 4.
		$\overline{\mathbb{N}}(h)$ <b>D</b> epart category boundaries when continuous variables were categorized
		$\Delta(b)$ Report category boundaries when continuous variables were categorized
		When continuous variables were categorized, boundaries are given
		When continuous variables were categorized, boundaries are given   (c) If relevant, consider translating estimates of relative risk into absolute risk for a
		When continuous variables were categorized, boundaries are given   [] (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Descriptive data    Outcome data   Main results	14* 15* 16	Numbers are clearly stated.   ⊠(b) Give reasons for non-participation are listed.   ⊠(c) Consider use of a flow diagram   Given the workflow is straightforward, we explained it in the text.   ⊠(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders   The first part of the Results section and Table 1 provide all descriptive data.   ⊠(b) Indicate number of participants with missing data for each variable of interest   Missingness for the main outcomes is reported at the beginning of the results.   Missingness for any variable of interest is indicated in the results tables or was accounted for in the statistical models   ⊠(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included   To be found in Tables 3 and 4.

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and
		sensitivity analyses
		Regression models, concordance/agreement analyses, and receiver operating
		characteristic curve analysis are described and presented in the Methods,
		Supplementary Materials, and Results.
Discussion		
Key results	18	Summarise key results with reference to study objectives
		All key results are summarized in the first paragraph of the Discussion and discussed
		in more detail in the following
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or
		imprecision. Discuss both direction and magnitude of any potential bias
		Limitations are extensively discussed in the first part of the Discussion.
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,
		multiplicity of analyses, results from similar studies, and other relevant evidence
		We extensively discuss all the limits in the interpretation of our study findings through
		the Discussion section
Generalisability	21	Discuss the generalisability (external validity) of the study results
		Generalizability of study findings is discussed
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if
		applicable, for the original study on which the present article is based
		Source of funding and role of funders are given.

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.